Pharmacovigilance in Egypt: QPPV Requirements, Adverse Event Reporting, and PSUR Obligations

Overview

Pharmacovigilance — the science of monitoring, detecting, and preventing adverse effects of pharmaceutical products — is a mandatory regulatory requirement in Egypt. The Egyptian Drug Authority (EDA) has strengthened its pharmacovigilance framework in recent years, aligning with ICH and WHO guidelines. For pharmaceutical companies with products registered in Egypt, meeting these obligations requires dedicated local capability.

The Egyptian Pharmacovigilance Framework

The Egyptian Pharmacovigilance Center, operating under the EDA, is responsible for overseeing drug safety across the Egyptian market. Its mandate includes:

• Collecting and evaluating adverse drug reaction (ADR) reports from healthcare professionals, patients, and marketing authorization holders
• Conducting signal detection and safety assessments
• Issuing safety communications and regulatory actions when new risks are identified
• Monitoring compliance of MAHs with their pharmacovigilance obligations

QPPV Requirements

What Is a QPPV?

A Qualified Person for Pharmacovigilance (QPPV) is the individual designated by the Marketing Authorization Holder to be responsible for the establishment and maintenance of the pharmacovigilance system. In Egypt, every MAH must designate a local QPPV.

QPPV Qualifications

The EDA requires the QPPV to have:

• A degree in pharmacy, medicine, or a related life science
• Demonstrated experience in pharmacovigilance activities
• Knowledge of the Egyptian regulatory framework and EDA reporting requirements
• Availability to fulfill PV responsibilities on an ongoing basis
• Residence in Egypt or the ability to fulfill local obligations through a designated deputy

QPPV Responsibilities

The local QPPV is responsible for:

• Overseeing all pharmacovigilance activities for the MAH's registered products in Egypt
• Ensuring adverse events are collected, assessed, and reported within regulatory timelines
• Maintaining the Pharmacovigilance System Master File (PSMF)
• Serving as the point of contact with the Egyptian Pharmacovigilance Center
• Ensuring that safety information from global sources is evaluated for local relevance

Adverse Event Reporting

Reporting Timelines

The EDA mandates specific timelines for reporting adverse events:

• Fatal or life-threatening serious unexpected ADRs — within 7 calendar days of first awareness, with a follow-up report within 8 additional days
• All other serious unexpected ADRs — within 15 calendar days of first awareness
• Non-serious ADRs — included in periodic safety reports

Report Format

Adverse event reports must be submitted in ICH E2B format, which includes:

• Patient demographics and medical history
• Suspected and concomitant medications
• Description of the adverse event including onset, duration, and outcome
• Reporter information and causality assessment
• Relevant laboratory and diagnostic test results

Data Sources

MAHs are expected to collect adverse event data from multiple sources:

• Spontaneous reports from healthcare professionals and patients in Egypt
• Post-marketing studies conducted in the Egyptian population
• Literature monitoring for published case reports relevant to registered products
• Global safety data that may have local relevance
• Social media and digital monitoring where applicable

Periodic Safety Update Reports (PSURs)

PSUR Requirements

MAHs must submit Periodic Safety Update Reports to the EDA at defined intervals:

• First two years post-approval — every 6 months
• Years three and four — annually
• After year four — every 3 years, or as specified by the EDA

PSUR Content

A PSUR must include:

• Summary of the product's safety profile during the reporting period
• Analysis of all adverse events received worldwide, with focus on Egyptian data
• Benefit-risk evaluation based on cumulative safety evidence
• Signal detection results and any emerging safety concerns
• Proposed risk minimization measures if applicable
• Updated patient exposure estimates

Risk Management Plans

For certain products — particularly new chemical entities, biologics, and products with known safety concerns — the EDA may require a Risk Management Plan (RMP) that includes:

• Safety specification — known and potential risks, missing information
• Pharmacovigilance plan — activities beyond routine PV to characterize risks
• Risk minimization measures — actions to reduce identified risks (educational materials, restricted distribution, monitoring requirements)

Building a Pharmacovigilance System

Companies entering Egypt need to establish or contract a pharmacovigilance system that includes:

1. Standard operating procedures covering all PV activities from case intake to regulatory submission
2. Safety database for recording, processing, and tracking adverse event reports
3. Medical assessment capability for evaluating case causality and seriousness
4. Regulatory reporting workflows configured for EDA-specific requirements and timelines
5. Quality management including periodic audits of PV processes and compliance metrics

Common Compliance Gaps

1. No designated local QPPV — relying solely on a global PV team without local representation does not meet EDA requirements
2. Late reporting — missing the 7-day or 15-day reporting deadlines can result in regulatory action
3. Incomplete case documentation — insufficient follow-up on reported cases leading to low-quality reports
4. PSUR delays — failing to submit periodic reports on schedule
5. No PSMF — lacking a maintained Pharmacovigilance System Master File that reflects actual PV practices

How Epidis Pharma Provides PV Support

Epidis Pharma offers pharmacovigilance services including local QPPV designation, adverse event case management, PSUR preparation and submission, signal detection support, and regulatory compliance monitoring. Our PV team operates within established SOPs aligned with ICH guidelines and EDA requirements, providing our partners with confidence that their pharmacovigilance obligations in Egypt are met consistently and on time.